FDA approves Zubsolv (Orexo) for treatment of Opioid Dependence

The FDA has approved sublingual Zubsolv (buprenorphine/naloxone), from Orexo, as maintenance treatment for people suffering from Opioid Dependence.

Studies indicate that Zubsolv was preferred by more than 8 out of 10 of the participants on all acceptance parameters tested: overall acceptability, taste masking, after taste experience, mouth-feel, and ease of administration. The study also confirmed a fast dissolve time. The product will be launched in September.